Portal de Periódicos da CAPES

Aerosol generating procedures, dysphagia assessment and COVID‐19: A rapid review

2020; Wiley; Volume: 55; Issue: 4 Linguagem: Inglês

10.1111/1460-6984.12544

1460-6984

Lee Bolton, Claire Mills, Sarah Wallace, Marian Brady,

Infection Control and Ventilation

In response to members' significant concerns and their request for an examination of the evidence relating to oropharyngeal dysphagia assessment, aerosol-generating procedures (AGPs) and associated risk of COVID-19 infection, the Royal College of Speech and Language Therapists (RCSLT) established a COVID-19 Advisory Group (see the appendix). The group aimed to review the evidence underpinning the current healthcare policies in relation to AGPs, dysphagia assessment, and risk of transmission of and infection with COVID-19 in response to urgent clinical information needs. Oropharyngeal dysphagia assessment is highly complex and may comprise a wide spectrum of interventions including, but not limited to, clinical (bedside) swallowing assessment, provision of therapeutic oral care, fibreoptic endoscopic evaluation of swallowing, videofluoroscopy swallowing study and cough reflex testing. In the UK, dysphagia assessment is often conducted by speech and language therapists (SLTs), though internationally (particularly in regions with no access to SLTs), other multidisciplinary team members may be responsible for this aspect of healthcare. Dysphagia screening will often draw on the skills of the wider multidisciplinary team with specialist nurses in acute stroke and stroke rehabilitation settings, for example, undertaking dysphagia screenings while SLTs undertake in depth dysphagia assessment and a more consultative role (Martino et al. 2014). Dysphagia assessment occurs in a range of clinical contexts where there are concerns about a patient's swallowing ability, including acute and critical care, outpatient departments, rehabilitation units, and community settings. The rapid review focused on clinical (bedside) swallowing assessment and the risk of COVID-19 transmission through aerosol emissions, the likelihood of aerosol emissions during dysphagia assessment and the evidence supporting the identification of the AGPs identified in COVID-19 healthcare recommendations. While a standard systematic review approach is preferable when establishing an evidence base for a defined intervention, this was not feasible in the context of the COVID-19 pandemic for several reasons. COVID-19 is a novel virus, distinct in many ways from other viral respiratory infections such as Severe Acute Respiratory Syndrome (SARS) or Middle East Respiratory Syndrome (MERS) (Wölfel et al. 2020). It was first reported in December 2019 in Wuhan, China, a country where the SLT profession is in its infancy. Early evidence specific to COVID-19 and dysphagia assessment was anticipated to be scarce. The pace of newly emerging COVID-19 literature and daily updates to national healthcare policies and recommendations resulted in a rapidly changing literature base which made a traditional in-depth systematic review approach unfeasible. Conducting a wider systematic search with broader inclusion criteria, such as 'viral transmission' and 'infection rates' and 'coughing' alone, for example, generated a greater number of references (but many irrelevant references based on pilot search strategies), take considerably more time to review and evaluate, but generate findings of questionable relevance to COVID-19 and the purposes of this review. Our rapid review methodology identified relevant literature through a narrow search strategy applied to the following databases (Medline, Embase, Global Health via Ovid and CINAHL via HDAS) using search strategies specific to the electronic database, but searching the following keywords (and variations) 'infection transmission', 'infection control', 'healthcare workers' and 'procedures' or 'dysphagia assessment' and for free-text terms 'aerosol generating procedures' or 'bio aerosols' and 'healthcare workers' (for a Medline search strategy example, see the Supplementary Materials). Grey literature sources NICE Evidence, Oxford CEBM COVID-19 Evidence Service and MedRxiv were also searched. We hand-searched JAMA, The Lancet and BMJ since December 2019, the UK Public Health England and Health Protection Scotland COVID-19 policy documents and references cited in those documents, and employed backwards citation searching of key papers identified in the search. We also used PubMed and Google search engines and communicated with the members of the RCSLT COVID-19 Advisory Group and other international experts. We included information relating to COVID-19 and dysphagia assessment, aerosol generation, risk of infection, transmission, coughing and SLTs. We also reviewed the underpinning evidence informing Public Health England and Health Protection Scotland lists of AGPs and risk of viral transmission or infection and considered to what extent SLTs or dysphagia assessment were included in that evidence base. All authors reviewed the literature, sharing their findings and supporting references with co-authors electronically. Through an iterative process, the search findings were collated and summarized with queries, clarifications or explanations. Remaining queries or discrepancies were resolved in a final videoconference discussion between all co-authors. An initial draft of the final review findings was shared with the wider COVID-19 Advisory Group for review and feedback. The World Health Organisation (WHO) recently concluded that, based on the current evidence, transmission of COVID-19 is primarily through respiratory droplets and contact routes (Modes of Transmission of Virus Causing COVID-19: Implications for IPC Precaution Recommendations 2020). A high viral load has been detected in the saliva of patients with COVID-19 with viral shedding observed up to 11 days after hospital admission (To et al. 2020b) and in a follow-up study, up to 25 days after symptom onset (To et al. 2020a). Viral shedding from throat swabs is reported for a median of 20.0 days (interquartile range (IQR) = 17.0–24.0) n = 137 survivors) and up to 37 days following symptom onset or until death (n = 54) (Zhou et al. 2020). Research suggests that patients with severe COVID-19, such as those who are critically ill, have a higher viral load and shed the virus for longer (Liu et al. 2020). Emission of respiratory droplets has been acknowledged as an important route of COVID-19 transmission (Guidance: Transmission Characteristics and Principles of Infection Prevention and Control 2020, To et al. 2020a). International and national COVID-19 policy and practice recommendations consistently highlight the emission of very small droplets (aerosols) from COVID-19 positive patients as increasing the risk of airborne transmission (Infection Prevention and Control and Preparedness for COVID-19 in Healthcare Settings. Second Update—31 March 2020 2020, COVID-19 Personal Protective Equipment (PPE) 2020). Aerosols may remain suspended in the air for a period of time, travel over a distance and may cause infection if inhaled (Aerosol Generating Procedures (AGPs) 2019). The dichotomous definition of aerosols and droplets is an arbitrary one, based on droplet size rather than a formal measure of infection risk or transmission rate (Shiu et al. 2019, Bourouiba 2020). The boundary of distinction varies across the literature (Howard et al. 2020). In realistic contexts, respiratory droplet emissions from a cough or a sneeze form a complex cluster of droplets across a range of sizes and from different levels of the respiratory system, within a turbulent gas cloud, under forward momentum (Bourouiba et al. 2014). In contrast to laboratory-based investigations of isolated droplets, the distance travelled by droplets emitted on a cough varies depending on a range of contextual factors: the patient's physiology, air flow currents, humidity and temperature (Zhu et al. 2006, Bourouiba et al. 2014). Other droplets may evaporate and remain suspended in the air for hours (Bourouiba et al. 2014). Coughing is an acknowledged source of aerosol droplet emissions (Aerosol Generating Procedures (AGPs) 2019, Guidance: Transmission Characteristics and Principles of Infection Prevention and Control 2020, Infection Prevention and Control and Preparedness for COVID-19 in Healthcare Settings. Second Update—31 March 2020 2020, Greenhalgh 2020, Howard et al. 2020) and saliva droplets emitted during forceful coughing have been highlighted as an important route for virus transmission (Judson and Munster 2019, Zhu et al. 2006). Dysphagia assessment comprises several components, of which cough testing (voluntary cough), reflexive cough and swallowing trials with samples of fluid and food are of particular relevance to this report (Martino et al. 2004, Watts et al. 2016). Reflexive coughing, secondary to aspiration of food or fluid into the lungs, is a common but unpredictable occurrence inherent to specialist dysphagia assessment (Smith Hammond and Goldstein 2006). The resultant coughing may be forceful, prolonged and not easily suppressed (Mazzone 2005, Addington et al. 2008; expert opinion of the Advisory Group). In addition, many dysphagia assessment protocols include some form of testing the presence and strength of a patients' voluntary cough as an indicator of their ability to protect their airway from aspiration of food or fluids (Watts et al. 2016). Undertaken by SLTs within 1 m of the patient, comprehensive dysphagia assessments are prolonged, lasting close to 10 min during which time coughing is tested or expected to occur (expert opinion of the Advisory Group). Ear, nose and throat (ENT) healthcare professionals have been reported to be at high risk of exposure and infection from COVID-19 due to their close proximity to patients' upper respiratory mucosa and interventional procedures that, similar to dysphagia assessments, induce cough (Givi et al. 2020, Lu et al. 2020). Given the proximity and prolonged exposure to frequent coughing during dysphagia assessment and strong theoretical risks, it is a reasonable assumption that SLTs are at a similarly high level of occupational risk of COVID-19 infection. Clinically, many patients presenting with COVID-19 (or suspected COVID-19) and dysphagia are predisposed to coughing during dysphagia assessments as a result of their concomitant respiratory conditions: upper respiratory tract symptoms of the COVID-19 infection, respiratory support requirements (Leder et al. 2015, Oomagari et al. 2015, Hori et al. 2016, Jaffe et al. 2018), reduced oxygen saturations (Steele and Cichero 2014), post-acute respiratory distress syndrome (Brodsky et al. 2017) or other comorbidities (e.g., chronic obstructive pulmonary disorder; Cvejic et al. 2011). Dysphagia itself may have resulted in an aspiration pneumonia while oral, pharyngeal and laryngeal weakness (secondary to intubation, intensive care unit (ICU) acquired weakness or neurological conditions) reduces the patients' ability to manage oral secretions and protect the airway (Scheel et al. 2016, Brodsky et al. 2017). Thus, patients presenting with COVID-19 and dysphagia are predisposed to a heightened and more frequent coughing through aspiration of saliva, food or liquids. AGPs are defined as 'any medical and patient care procedure that results in the production of airborne particles (aerosols)' (Aerosol Generating Procedures (AGPs), 2020). At the time of writing, there is no consensus on a definitive list of healthcare procedures that are AGPs (Judson and Munster 2019) with variations in medical and care procedures considered to be AGPs across national policies (table 1) (Thompson et al. 2013, Shiu et al. 2019, Use of PPE to Support Infection Prevention and Control Practice when Performing Aerosol Generating Procedures on Confirmed or Clinically Suspected COVID-19 Cases in a Pandemic Situation 2020). One recent review distinguished between AGPs that resulted in the creation or dispersion of aerosols and procedures that induced a patient to produce them (Judson and Munster 2019). Where possible, research evidence relating to acute respiratory infection transmission from patients to healthcare professionals in the context of specific healthcare procedures is used to identify AGP considered to be at high risk (Infection Prevention and Control of Epidemic- and Pandemic-Prone Acute Respiratory Infections in Health Care 2014). The evidence base is limited, however, and biased in the selection of procedures investigated as sources of transmission (Tran et al. 2012, Thompson et al. 2013) later synthesized in reviews and meta-analyses and, in turn, underpinning clinical recommendations. Recent WHO guidelines on infection prevention and control (Infection Prevention and Control of Epidemic- and Pandemic-Prone Acute Respiratory Infections in Health Care 2014), for example, refer to a systematic review in support of their classification of AGP and increased risk of SARS infection transmission (Tran et al. 2012). The systematic reviewers, however, used an earlier WHO-generated list of AGPs to inform their review inclusion criteria. The reviewers highlight the lack of information available on procedures known to induce coughing and associated aerosol emissions and the possible risk of infection transmission associated with those procedures (Tran et al. 2012). Thus, as stated by the Centers for Disease Control and Prevention: 'there is neither expert consensus, nor sufficient supporting data, to create a definitive and comprehensive list of AGPs for healthcare settings' (Healthcare Infection Prevention and Control FAQs for COVID-19 2020). New AGPs continue to be identified through literature reviews of conflicting studies, theoretical risk of aerosol generation and expert consensus; non-invasive ventilation and high flow nasal oxygen, for example, are two recent inclusions in UK health protection policy documents (Aerosol Generating Procedures (AGPs) 2019). The research evidence to date on the risk of infection and transmission rate has focused on predefined AGPs. Within the systematic review of AGPs and risk of SARS transmission (Tran et al. 2012) all 10 included studies focused on intubation and ventilation procedures conducted by medical and/or nursing staff. Half did not appear to include SLTs; three of 10 studies focused on intubation and tracheostomy procedures only; two of 10 were specific to nursing or medical staff only. The remaining five studies (n = 1764 staff participants) referred to 'other staff' (n = 150), but no SLTs were described, nor was dysphagia assessment. Three studies recorded healthcare professionals' contact with patient sputum and/or respiratory secretions, each reporting a significantly increased risk of infection. The quality of the primary research studies was poor, and the review syntheses were rated as low quality (Tran et al. 2012). As another example, a recent cluster randomized controlled trial evaluated the effectiveness of N95 respirators versus medical masks in reducing the risk of influenza transmission to healthcare professionals (Radonovich et al. 2019). The large trial took place across several US outpatient settings where dysphagia assessment is likely to be rare. SLTs were unreported amongst the 16 professionals recorded in the trial staff participant record form. The AGP recorded as undertaken by the staff included: intubation, respiratory/airway suctioning, nebulizer treatments and nasopharyngeal aspiration. While some research on AGP and risk of transmission exists, the evidence relating to dysphagia assessment and risk is absent, though this does not reflect an absence of risk. Induction of sputum following the administration of saline into the lungs, moistening and loosening respiratory secretions, shares an infection risk profile similar to dysphagia induced, prolonged and forceful coughing when food or fluid is aspirated into the lungs. The induction of sputum is currently considered an AGP (Aerosol Generating Procedures (AGPs) 2019). The recent European Centre for Disease Prevention and Control recommendations (Infection Prevention and Control and Preparedness for COVID-19 in Healthcare Settings. Second Update—31 March 2020 2020) highlighted the risk of coughing or sneezing induced while collecting nasopharyngeal diagnostic respiratory samples, and the associated risk of aerosol production. Thus, there is consensus across the healthcare and infection control community that procedures known to induce prolonged and forceful coughing result in the production of aerosols which in turn place healthcare professionals at greater risk of infection. There is general agreement across the literature and guidelines that in such cases precautionary steps should be taken to reduce the risk of infection for healthcare professionals. We have presented evidence that forceful coughing generates aerosols and the emerging evidence which indicates that COVID-19 is likely transmitted through aerosol (and other) routes. We described SLTs' close and prolonged contact with forceful coughing, induced during standard dysphagia assessment procedures and why patients with COVID-19 are likely to be at greater risk of coughing. We examined the criteria used to establish the current list of AGP and found a lack of consensus and a high risk of selection bias, focusing only on risk of infection based on previously identified AGPs. We highlighted evidence that suggests a greater risk of transmission and infection of healthcare professionals that experience frequent and repeated contact with patients' respiratory secretions or sputum in the context of a novel virus, non-immunity and high infectivity. Amongst the limitations of our rapid review is the depth of searching and analysis of primary research findings that could be undertaken within a short timeframe. We were unable to identify definitive evidence linking dysphagia assessment to a higher risk of COVID-19 transmission. However, it is important to note that we also failed to identify evidence that the procedure does not increase the risk of transmission. The strength of our rapid review includes the expert dysphagia authorship informed by a UK-wide expert advisory group, a thorough search of published and grey literature, undertaken in a timely manner to address an urgent clinical question in the context of the COVID-19 pandemic. In the context of the available evidence and expert consensus, healthcare providers and infection control policy-makers should take precautionary steps to reduce the risk of COVID-19 transmission and infection while undertaking dysphagia procedures (Infection Prevention and Control and Preparedness for COVID-19 in Healthcare Settings. Second Update—31 March 2020 2020). The safety of healthcare workers and expert consensus should prevail. The review was prepared on behalf of the Royal College of Speech and Language Therapists (RCSLT) COVID-19 Advisory Group. All co-authors, L. B., C. M., S. W. and M. C. B., contributed equally to the drafting and review of the manuscript. The final draft was approved by the wider Advisory Group, as listed in the appendix. Kirsten Elliott, NHS Support Librarian, Imperial College London, for developing the electronic search strategy and contributing to the literature searching; colleagues at the Royal College of Speech and Language Therapists (RCSLT), British Association of Parenteral and Enteral Nutrition, British Thoracic Society, ENT-UK, European Society of Swallowing Disorders, Intensive Care Society, National Tracheostomy Safety Project, UK Swallowing Research Group and British Association of Stroke Physicians for support. The views expressed here are those of the authors, members of the Advisory Group and the RCSLT and do not necessarily reflect the views of the National Health Service (NHS), the authors' affiliated institutions or funding organizations. Katherine Behenna, Lead for Head & Neck and Voice Disorders SLT Service, Nottingham University Hospitals Trust Lee Bolton, Clinical Lead Speech & Language Therapist/Improvement Coach, Imperial Health Charity; Pre-doctoral Research Fellow, Imperial College London Grainne Brady, Clinical Lead Speech & Language Therapist Head & Neck, The Royal Marsden NHS Foundation Trust Gemma Clunie, Clinical Specialist SLT (Airways/ENT) Imperial College Healthcare NHS Trust; HEE/NIHR Clinical Doctoral Fellow, Imperial College London Dr Margaret Coffey, Clinical Service Lead, SLT (Head and Neck/ENT), Honorary Clinical Research Fellow, Imperial College London Dr Hannah Crawford, Professional Head of Speech & Language Therapy, Tees, Esk & Wear Valleys NHS Foundation trust Zoe Dalal, Team lead, Wellington Hospital Pauline Downie, Professional Lead for Speech and Language Therapy, NHS Lanarkshire Dr Roganie Govender, Consultant SLT & NIHR Clinical Lecturer, University College London Hospital, Head and neck Cancer Centre; Hon Senior Research Associate, University College London, Research Department of Behavioural Science & Health, Epidemiology & Public Health Jemma Haines, Consultant Respiratory Speech & Language Therapist, NIHR Manchester BRC PhD Fellow & Service Lead for Manchester Airways Service, Manchester University NHS FT Lauren Isaacs, Principal Speech & Language Therapist, Adult Community Speech & Language Therapy, Norfolk Community Health and Care NHS Trust Gemma Jones, Clinical Lead SLT, Cardiff and Vale University Health Board; Highly Specialist SLT Critical Care, Cwm Taf Morgannwg University Health Board Hannah Lewthwaite, Speech and Language Therapist, Clinical Expert Pathway Lead for Dysphagia, Solent NHS Trust Julia McDowall, Clinical Lead Speech and Language Therapist (intensive care/neurosurgery), North Bristol NHS Trust Dr Jackie McRae, Associate Professor and Director of Research, School of Allied Health, Midwifery and Social Care, University of London; Consultant Speech and Language Therapist, University College London Hospital Claire Mills, Clinical Specialist Speech and Language Therapist in Critical Care; NIHR Clinical Doctoral Research Fellow, University of Leeds Suzannah Partner, Clinical Lead Speech and Language Therapist, Community Neurorehabilitation, Central London Community Healthcare NHS Trust Francesca Pepper, Clinical Lead Specialist, Adult Speech and Language Therapy, Hertfordshire division, Central London Community Healthcare Professor Sue Pownall, Head of Speech and Language Therapy and Clinical Lead in Dysphagia, Academic Director Therapeutics & Palliative Directorate, Sheffield Teaching Hospital NHS Foundation Trust Dr Justin Roe, Consultant and Joint Head, Department of Speech, Voice and Swallowing, The Royal Marsden NHS Foundation Trust; Clinical Service Lead, Speech & Language Therapy, National Centre for Airway Reconstruction/Department of Otolaryngology, Head and Neck Surgery, Imperial College Healthcare NHS Trust; Honorary Lecturer, Division of Surgery, Department of Surgery and Cancer, Imperial College London Alex Stewart, NIHR Clinical Doctoral Research Fellow, Specialist Speech and Language Therapist, Great Ormond Street Hospital/UCL Sarah Wallace, Consultant SLT (Critical care and dysphagia), Wythenshawe Hospital, Manchester University NHS Foundation Trust; Chair RCSLT Tracheostomy Clinical Excellence Network; NIHR Research Associate Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.